Horizon Therapeutics to acquire MedImmune Spinout Viela Bio in deal with equity value of $3.05 billion

Published on :

During a conference call this morning, Horizon Therapeutics Chief Executive Officer Tim Walbery pointed to the depth of Viela’s research and development programs, the company’s understanding of common mechanisms of autoimmunity, and its strong legacy management from MedImmune as net positives for Horizon. During the call, Walbery said Viela is a “strong strategic fit” that will drive long-term and sustainable growth for Horizon.

The Top Biotech Companies That are Hiring – June 2020

Published on :

The Top Biotech Companies That are Hiring – June 2020 June 9, 2020 Despite the uncertainty created by the COVID-19 pandemic, companies across the BioHealth Capital Region (BHCR) continue to [….]

Industry Leaders Outline Best Strategies for Attracting Talent in the BioHealth Capital Region

Published on :

Industry Leaders Outline Best Strategies for Attracting Talent in the BioHealth Capital Region Recruiting and attracting talent is one of the top priorities and challenges for biotech and life science [….]

BioHealth Capital Region Startups Raised More Than $739M in 2019

Published on :

BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]

Why Developing Cures for Rare Disease Isn’t So Rare Anymore

Published on :

Why Developing Cures for Rare Disease Isn’t So Rare Anymore These Six Maryland Biotech Companies Are Seeing Success in Targeting Rare Diseases September 3, 2019 Groundbreaking technology and scientific advancements, [….]